Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) for Relapsed and Refractory Multiple Myeloma (RRMM): Results from a Pharmacoeconomic Evaluation

  • Michael O'Dwyer

Research output: Other contribution (Published)Other contribution

Original languageEnglish (Ireland)
Media of outputAbstract
Volume124
Publication statusPublished - 1 Dec 2014

Cite this